Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects

In addition to showing antidiabetic effects, sodium–glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Yoshiaki, Shimizu, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627935/
https://www.ncbi.nlm.nih.gov/pubmed/36338417
http://dx.doi.org/10.1016/j.jacasi.2022.03.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627935/
https://www.ncbi.nlm.nih.gov/pubmed/36338417
http://dx.doi.org/10.1016/j.jacasi.2022.03.009

Ejemplares similares